ENCBS613DXG / cell line
Summary
- Status
- released
- Term name
- HepG2
- Term ID
- EFO:0001187
- Summary
- Homo sapiens HepG2 cell line genetically modified (insertion) using transduction, genetically modified using CRISPRi (pgRNA) 0 days after the sample was treated with 2 μg/mL Puromycin for 2 days, 0.2 μg/mL Puromycin for 2 days
- Culture start date
- 2019-03-01
- Culture harvest date
- 2019-04-20
Attribution
ENCODE4 project
- Lab
- Bing Ren, UCSD
- Award PI
- Yin Shen, UCSF
- Submitted by
- Bin Li
- Source
- ATCC
- Project
- ENCODE
- External resources
- Aliases
- bing-ren:BC19B_HepG2_D0_B2_BC90
Treatment details
- Treatment
- 2 μg/mL Puromycin (CHEBI:17939) for 2 days
- Type
- chemical
- Purpose
- selection
- Treatment
- 0.2 μg/mL Puromycin (CHEBI:17939) for 2 days
- Type
- chemical
- Purpose
- selection
Genetic modifications
Accession | Category | Purpose | Method | Nucleic acid delivery method | Site |
---|---|---|---|---|---|
ENCGM554RTS | insertion | expression | transduction | ||
ENCGM353IMQ | CRISPRi | characterization | CRISPR |
Donor information
- Status
- released
- Accession
- ENCDO000AAC
- Aliases
- encode:donor of HepG2, bradley-bernstein:Donor of HepG2
- Species
- Homo sapiens
- Life stage
- child
- Age
- 15 years
- Sex
- male
- Health status
- hepatocellular carcinoma
- Ethnicity
- European
- External resources
- References